Company research
Eledon Pharmaceuticals, Inc.
CIK 1404281Updated Sep 27, 2026
SecurityELDN · NASDAQ · equity
Name history
Eledon Pharmaceuticals, Inc. · through Sep 4, 2026Novus Therapeutics, Inc. · through Dec 22, 2020Tokai Pharmaceuticals Inc · through May 4, 2017
ELDN price & chart
Loading TradingView…
NASDAQ:ELDN on TradingView ↗About the company
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40L biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, islet cell transplantation, liver transplantation and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.
In the news
Recent filings
S-8 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
SCHEDULE 13G filing
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Submission of Matters to a Vote of Security Holders
Items 5.03, 5.07, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 169,009,000Source | 177,405,000Source | — | 92,793,000Source |
| GoodwillUSD | — | — | — | 0Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 22,808,000Source | 20,549,000Source | — | 56,409,000Source |
| Assets, CurrentUSD | 135,688,000Source | 143,730,000Source | — | 59,518,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,352,000Source | 3,552,000Source | — | 3,109,000Source |
| Operating Lease, Right-of-Use AssetUSD | 613,000Source | 926,000Source | — | 739,000Source |
| Other Assets, NoncurrentUSD | 322,000Source | 363,000Source | — | 150,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 32,230,000Source | 59,265,000Source | 63,017,000Source | 8,610,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 75,000Source | 60,000Source | 23,000Source | 14,000Source |
| Retained Earnings (Accumulated Deficit)USD | -401,203,000Source | -355,586,000Source | -279,397,000Source | -202,865,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 24,000Source | 26,000Source | — | — |
| Stockholders' Equity Attributable to ParentUSD | 81,085,000Source | 62,446,000Source | 43,768,000Source | 84,183,000Source |
| Additional Paid in Capital, Common StockUSD | 482,189,000Source | 417,946,000Source | 323,142,000Source | 287,034,000Source |
| Liabilities and EquityUSD | 169,009,000Source | 177,405,000Source | — | 92,793,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 18,344,000Source | 11,577,000Source | — | 6,475,000Source |
| Operating Lease, Liability, CurrentUSD | 358,000Source | 314,000Source | — | 363,000Source |
| Accounts Payable, CurrentUSD | 3,627,000Source | 5,833,000Source | — | 2,200,000Source |
| Operating Lease, Liability, NoncurrentUSD | 283,000Source | 640,000Source | — | 383,000Source |
| Deferred Income Tax Liabilities, NetUSD | 2,187,000Source | 2,183,000Source | — | 1,752,000Source |
| Additional Financial Items | ||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 133,300,000Source | — | — | — |
| Deferred Tax Liabilities, NetUSD | 2,187,000Source | 2,183,000Source | — | 1,752,000Source |
| Short-term InvestmentsUSD | 110,528,000Source | 119,629,000Source | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Deferred Income Tax Expense (Benefit)USD | 5,000Source | 431,000Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -62,341,000Source | -47,271,000Source | -39,527,000Source | -28,424,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 10,793,000Source | -70,314,000Source | -45,287,000Source | — |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 53,807,000Source | 133,522,000Source | 33,017,000Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 2,259,000Source | 15,937,000Source | -51,797,000Source | -28,424,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 22,808,000Source | 20,549,000Source | 4,612,000Source | 56,409,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | 28,000Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 10,451,000Source | 13,122,000Source | 6,545,000Source | 8,153,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 133,300,000Source | — | 51,100,000Source | — |
| Gain (Loss) on Termination of LeaseUSD | — | 10,000Source | — | — |
| General and Administrative ExpenseUSD | 16,984,000Source | 18,613,000Source | 12,688,000Source | 12,700,000Source |
| GoodwillUSD | — | — | 0Source | 0Source |
| Goodwill, Impairment LossUSD | — | — | 0Source | 48,648,000Source |
| Income Tax Expense (Benefit)USD | 35,000Source | 431,000Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -45,617,000Source | -36,184,000Source | -116,537,000Source | -87,966,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -42,328,000Source | — | — | — |
| Operating ExpensesUSD | 83,251,000Source | 70,577,000Source | 43,000,000Source | 88,428,000Source |
| Operating Lease, ExpenseUSD | 400,000Source | 400,000Source | 400,000Source | 300,000Source |
| Other Nonoperating Income (Expense)USD | 4,220,000Source | 3,924,000Source | 2,674,000Source | 462,000Source |
| Proceeds from Stock Options ExercisedUSD | 230,000Source | 215,000Source | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -43,000,000Source | -88,428,000Source |
| Other Nonoperating Income (Expense)USD | 4,220,000Source | 3,924,000Source | 2,674,000Source | 462,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -45,582,000Source | -35,753,000Source | -116,537,000Source | -87,966,000Source |
| Income Tax Expense (Benefit)USD | 35,000Source | 431,000Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -45,617,000Source | -36,184,000Source | -116,537,000Source | -87,966,000Source |
| Earnings Per Share, BasicUSD per share | -0.52Source | -0.75Source | -4.73Source | -6.16Source |
| Earnings Per Share, DilutedUSD per share | -0.52Source | -0.75Source | -4.73Source | -6.16Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 81,836,246Source | 48,543,787Source | 24,619,197Source | 14,285,254Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 81,836,246Source | 48,543,787Source | 24,619,197Source | 14,285,254Source |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | 30,000Source | — | — | — |
| General and Administrative ExpenseUSD | 16,984,000Source | 18,613,000Source | 12,688,000Source | 12,700,000Source |
| Goodwill, Impairment LossUSD | — | — | 0Source | 48,648,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -45,781,000Source | -35,951,000Source | -116,736,000Source | -88,159,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -42,328,000Source | — | — | — |
| Operating ExpensesUSD | 83,251,000Source | 70,577,000Source | 43,000,000Source | 88,428,000Source |
| Operating Lease, ExpenseUSD | 400,000Source | 400,000Source | 400,000Source | 300,000Source |
| Research and Development ExpenseUSD | 66,267,000Source | 51,964,000Source | 30,312,000Source | 27,080,000Source |
Filing attachments
eldn-ex99_1.htm · 8-K · 2026-08-13
EX-99.1 2 eldn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights Successful End-of-Phase 2 meeting with FDA supports advancement of tegoprubart into a global Phase 3 kidney transplantation trial, on track to initiate in late 2026 Long-term Phase 2 BESTOW data presented at ATC 2026 demonstrated sustained higher kidney function and improved patient-reported outcomes with tegoprubart compared with tacr…
Read attachment ↗eldn-ex99_1.htm · 8-K · 2026-05-13
EX-99.1 2 eldn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights 100% insulin independence achieved in 10 patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study FDA Orphan Drug designation granted to tegoprubart for the prevention of allograft rejection in liver transplantation Cash, cash equivalents and short-term investments totaled $1…
Read attachment ↗eldn-ex99_1.htm · 8-K · 2026-03-19
EX-99.1 2 eldn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results Reported updated results from 12 patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study Presented 24-month follow-up data from Phase 1b long-term extension study which continues to support the favorable safety and tolerability profile of tegoprubart Tegoprubart granted Orphan…
Read attachment ↗eldn-ex4_1.htm · 8-K · 2026-01-02
EX-4.1 2 eldn-ex4_1.htm EX-4.1 EX-4.1 Exhibit 4.1 PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK ELEDON PHARMACEUTICALS, INC. Warrant Shares: ________ Issue Date: ________, 20__ Initial Exercise Date: ________, 20__ THIS PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, __________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after…
Read attachment ↗eldn-ex99_1.htm · 8-K · 2025-11-14
EX-99.1 2 eldn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results Data from Phase 2 BESTOW trial demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrolimus Data supports advancement into Phase 3 development as a potential new standard for the prevention of kidney transplant rejection S…
Read attachment ↗d28785dex41.htm · 8-K · 2025-11-13
EX-4.1 3 d28785dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK ELEDON PHARMACEUTICALS, INC. Warrant Shares: _______ Issue Date:______, 20__ Initial Exercise Date: _______, 20__ THIS PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after…
Read attachment ↗